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y 8, 2013.he aim of this study was to determine the value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in adults
with congenital heart disease (CHD) and investigate its relationship with ventricular function and exercise capacity.Background NT-proBNP may detect early deterioration in cardiac function.Methods In this cross-sectional study, extensive echocardiography, exercise testing, and NT-proBNP measurements were
performed on the same day in consecutive adult patients with CHD.Results In total, 475 patients were included in this study (mean age of 34  12 years, 57% male, 90% New York Heart
Association class I). The median NT-proBNP level was 15.1 pmol/l (interquartile range [IQR]: 7.1 to 31.3 pmol/l),
and the NT-proBNP level was >14 pmol/l in 53% of patients. The highest NT-proBNP levels were observed in
patients with Fontan circulation (36.1 pmol/l [IQR: 14.4 to 103.8 pmol/l]) and a systemic right ventricle (RV)
(31.1 pmol/l [IQR: 21.8 to 56.0 pmol/l]), and the lowest values were seen in patients with aortic coarctation
(7.3 pmol/l [IQR: 2.8 to 19.5 pmol/l]). NT-proBNP levels correlated with age (r ¼ 0.39, p < 0.001) and were
higher in women (median of 21.7 vs. 10.4 pmol/l; p < 0.001). In patients with aortic stenosis or aortic
coarctation, NT-proBNP levels correlated with diastolic function parameters of E/E0 ratio (r ¼ 0.40, p < 0.001)
and left atrial dimension (r ¼ 0.36, p < 0.001). In patients with a systemic RV, NT-proBNP levels correlated with
RV annulus diameter (r ¼ 0.31, p ¼ 0.024). In patients with tetralogy of Fallot, the strongest correlations were
observed with left atrial dimension (r ¼ 0.46, p < 0.001) and left ventricular ejection fraction (r ¼ 0.37,
p < 0.001). NT-proBNP levels were associated with exercise capacity (n ¼ 198) (maximum workload: b ¼ 0.08,
p ¼ 0.021) and peak oxygen uptake (b ¼ 0.012, p ¼ 0.011) in a multivariable regression model adjusted
for age and sex.Conclusions NT-proBNP levels in adults with CHD clearly differ by diagnosis and are related to echocardiographic parameters and
exercise capacity. Disease-speciﬁc correlations contribute to the understanding of the main hemodynamic problems
per diagnosis. Follow-up data are needed to elucidate the additional prognostic value. (J Am Coll Cardiol
2013;62:1203–12) ª 2013 by the American College of Cardiology FoundationThe remarkable improvement in survival due to the success
of cardiac surgery, anesthesia, intensive care, and specialist
(pediatric) cardiological care has caused a rapid increase in
the number of adults with congenital heart disease (CHD)
(1,2). As a result of this success, late complications are more
often encountered, such as ventricular dysfunction, need
for reintervention, arrhythmias, and sudden death. TheseThoraxcenter, Erasmus Medical Center, Rot-
s have reported that they have no relationships
o disclose.
3; revised manuscript received June 18, 2013,adverse effects have important consequences for patients’
prognosis and quality of life (3). Therefore, early detection of
deterioration in ventricular function and adequate timing of
(re)interventions is crucial.
N-terminal pro-B-type natriuretic peptide (NT-proBNP),
known as the inactive fragment of prohormone of brain
natriuretic peptide, is primary secreted by cardiac myocytes
in response to abnormal ventricular wall stress and loading
conditions (4). NT-proBNP is a well-known marker of
ventricular dysfunction and heart failure in patients with
acquired heart disease (5). The additional use of NT-proBNP
as a marker for ventricular dysfunction in patients with
CHD has been suggested (6). However, NT-proBNP has
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1204only been studied in a small
number of patients with a speciﬁc
type of congenital cardiac lesion,
and the relationship between
NT-proBNP level and cardiac
function has not been assessed
at all (7). The wide spectrum of
congenital heart lesions, each
with their own degree of com-
plexity and complications, sug-
gests that disease-speciﬁc use of
the marker might be required (8).
Furthermore, not all diagnostic
and treatment options that are
beneﬁcial in patients with acquired
heart disease can be extrapolated
to patients with CHD, as has
been shown with medical treat-
ment of heart failure (9).
The aim of this study was to
evaluate the value of NT-
proBNP in adults with CHD
and investigate its relationship
with cardiac function and exer-
cise capacity.Methods
Study sample. Patients were recruited consecutively at the
adult CHD outpatient clinic of the Erasmus Medical Center
between May 2010 and October 2012. The following
congenital cardiac diagnoses were included: aortic valvular
stenosis (AoS), aortic coarctation (CoA), atrial septal defect,
tetralogy of Fallot (ToF) (also including patients with
pulmonary atresia and ventricular septal defect), trans-
position of the great arteries (TGA) corrected by arterial
switch operation (ASO), systemic right ventricle (RV)
(TGA corrected by Mustard procedure or congenitally
corrected TGA), and Fontan circulation. Of all eligible
patients, 95% agreed to participate. Exclusion criteria were
deﬁned as renal impairment (serum creatinine level >200
mmol/l) and age younger than 18 years.
Medical ethics and quality of data. The local medical
ethics committee approved the study protocol. Written
informed consent was obtained from all study participants.
Several measures were taken to ensure optimal data quality.
When patient enrollment was completed, one investigator
compared the data entered in the electronic case report form
with hospital records of 30 randomly selected study patients
(6%), which were all in accordance. Before further analyses
were conducted, manual edit checks were performed by the
investigators to search for missing data, contradictory data
entries, and values that were out of the speciﬁed normal
range.
Clinical characteristics. On the day of inclusion in the
study, all 475 patients underwent detailed 2-dimensionaltransthoracic echocardiography, 12-lead electrocardiog-
raphy, and laboratory testing. A total of 198 patients also
underwent bicycle ergometry on the same day. The following
patient characteristics were recorded: age, sex, type
of congenital heart defect, history of prior interventions, body
mass index, New York Heart Association (NYHA) func-
tional class, blood pressure, heart rate, and oxygen saturation.
Echocardiography. Two-dimensional transthoracic echo-
cardiography was performed by experienced sonographers
using a commercially available system (iE33, Philips, Best,
the Netherlands). Dimensions of the left ventricle (LV) (end-
diastolic and end-systolic endocardial diameter), RV (annulus
and apex-base distance), left atrium (4-chamber longitudinal
and transversal diameter as well as parasternal long axis
diameter), and right atrium (4-chamber longitudinal and
transversal diameter) were measured. All ventricular measures
were indexed for body surface area. Left ventricular systolic
function was assessed by left ventricular ejection fraction using
the biplane modiﬁed Simpson rule (10). Right ventricular
function was assessed by measurement of right ventricular
fractional area change (FAC) and tricuspid annulus plane
systolic excursion. In patients with an RV supporting the
systemic circulation, right ventricular FAC and tricuspid
annulus plane systolic excursion were used as systemic ventricle
function measures. Furthermore, diastolic function was
assessed using pulsed wave Doppler signals of the mitral or
tricuspid valve inﬂow (E, A, E/A ratio, and deceleration
time) and septal tissue Doppler imaging (E0). For the
measured dimensions and function parameters, approxi-
mately 95% of the images were of sufﬁcient quality.
Exercise test. Maximal exercise capacity (workloadmax) and
maximal oxygen uptake (VO2max) were assessed by bicycle
ergometry. Exercise test results were only obtained in
patients undergoing bicycle ergometry for routine clinical
follow-up (n ¼ 198). Workload was increased stepwise with
10 to 20 W/min. The results of exercise capacity were
compared with the results of healthy subjects adjusted for
age, sex, and body height and weight. Workloadmax and
VO2max were considered decreased when <85% of the pre-
dicted value was achieved. Performance was considered
maximal when a respiratory quotient of 1.1 was reached.
Laboratory testing. Peripheral venous blood samples were
obtained from all participants after they had rested for at
least 30 minutes. Plasma and serum were separated imme-
diately after collection of blood samples, and NT-proBNP,
creatinine, and hemoglobin levels were measured. NT-
proBNP levels were determined using the Elecsys system
(Roche Diagnostics, Basel, Switzerland). The cutoff value of
normal in our hospital is 14 pmol/l.
Statistical analysis. Categorical variables are summarized
as frequencies and percentages, and continuous variables
with a normal distribution are reported as mean  SD. We
report median values with interquartile range (IQR) in case
of a non-normal distribution. Differences between cardiac
diagnoses were compared using the Student unpaired t test
or Wilcoxon rank sum test. Differences between more than
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12052 groups were investigated with 1-way analysis of variance or
Kruskal-Wallis test. Because NT-proBNP values were not
normally distributed, the variable was log transformed to
create a normal distribution for further statistical analyses.
When the test outcome comprised log-transformed NT-
proBNP, these values were transformed backward to more
informative NT-proBNP values. Correlation analyses
between logNT-proBNP values and patient characteristics
were performed using the Pearson correlation test or
Spearman correlation test. A linear regression model was
used to evaluate the relationship between NT-proBNP
values and echocardiographic and bicycle ergometry
parameters adjusted for age and sex.
All statistical tests were 2 sided, and a p value of <0.05
was considered statistically signiﬁcant. The Statistical
Package for Social Sciences version 21.0 (SPSS, Chicago,
Illinois) was used for all statistical analyses.
Results
A total of 475 patients (mean age of 34  12 years, 57%
male) were included in the study. Baseline characteristics are
listed in Table 1. All patients had a creatinine level <200
mmol/l (mean of 76.3  18.5 mmol/l).
The median NT-proBNP level was 15.1 [IQR: 7.1 to
31.3] pmol/l, and was elevated in 53% of all patients. The
distribution of NT-proBNP levels varied by diagnostic
category (Fig. 1). Patients with a systemic RV (TGA cor-
rected by Mustard procedure and congenitally corrected
TGA) (median NT-proBNP level 31.1 [IQR: 21.8 to 56.0]
pmol/l) or Fontan circulation had signiﬁcantly higher NT-
proBNP levels than patients with less complex CHD
lesions (mean of 34.9 [IQR: 21.4 to 59.9] pmol/l vs. 12.7
[IQR: 6.0 to 25.2] pmol/l, p < 0.001).
NT-proBNP levels and patient characteristics. Levels of
NT-proBNP were higher in women than in men (mean of
22.3 [IQR: 11.5 to 38.2] vs. 11.5 [IQR: 4.8 to 24.8] pmol/l,
p < 0.001). Furthermore, mean NT-proBNP levels in-
creased with worsening NYHA functional class (NYHA
class I: 13.3 [IQR: 6.6 to 26.7] pmol/l; NYHA class II: 42.7
[IQR: 19.7 to 120.0] pmol/l; NYHA class III: 172.5 [IQR:
95.4 to 279.1] pmol/l; p < 0.001) (Fig. 2A). In patients with
NYHA class I, 50% had NT-proBNP levels above the upper
limit of normal (14 pmol/l). A signiﬁcant correlation
between NT-proBNP level and age was observed (r ¼ 0.39,
p < 0.001) (Fig. 2C). No relationship with blood pressure or
body mass index was found.
NT-proBNP levels and electrocardiogram. Patients with
atrial ﬁbrillation or atrial ﬂutter (3%) at the time of clinical
assessment had signiﬁcantly higher NT-proBNP levels than
patients in sinus rhythm (87%) or with an artiﬁcial paced
rhythm (7%) (p < 0.001) (Fig. 2B). A signiﬁcant relationship
between NT-proBNP level and QRS duration was observed
(p ¼ 0.005) (Fig. 2D), which was mainly driven by the
correlations in patients with TGA after Mustard correction
(r ¼ 0.41, p ¼ 0.005) and ToF (r ¼ 0.23, p ¼ 0.004).Echocardiographic measurements. An overview of all
echocardiographic measurements obtained for each diag-
nosis is presented in Table 2. In patients with a systemic LV,
systolic ventricular function was normal (ejection fraction
>50%) or only mildly decreased. In 92% of the patients with
a systemic RV, impaired right ventricular function, deﬁned
as a right ventricular FAC <35%, was found (median RV
FAC of 24.2% [IQR: 19% to 29%]). Enlarged right
ventricular annulus diameters were observed in patients with
a systemic RV and ToF.
Echocardiographic parameters and NT-proBNP levels.
All correlations between NT-proBNP levels and echocar-
diographic parameters are presented in Table 3.
CARDIAC DIMENSIONS. A positive relationship between NT-
proBNP level and left ventricular dimensions indexed for
body surface area was found, which remained signiﬁcant
after adjustment for age and sex. The strongest correlations
between NT-proBNP level and left ventricular dimensions
were seen in patients with AoS and patients with ToF. A
positive correlation between NT-proBNP level and indexed
right ventricular annulus dimension was observed in patients
with a systemic RV and ToF. Furthermore, left atrial di-
mensions measured in 3 directions correlated signiﬁcantly
with NT-proBNP level (only the correlation with left atrial
longitudinal dimension measured in the 4-chamber view is
shown). No relationship between NT-proBNP level and
ventricular wall thickness was observed.
SYSTOLIC FUNCTION. A signiﬁcant negative correlation
between left ventricular ejection fraction and NT-proBNP
level was observed and was mainly driven by the signiﬁ-
cant correlations in patients with ToF (r ¼ 0.37,
p < 0.001) and patients with AoS (r ¼ 0.27, p ¼ 0.033).
After adjustment for age and sex, the relationship remained
signiﬁcant. Right ventricular function, deﬁned as right
ventricular FAC, and NT-proBNP level were signiﬁcantly
related in the total group as well. This result was mainly
driven by the ﬁndings in patients with ToF and the trend
between NT-proBNP level and right ventricular FAC in
patients with a systemic RV. Mixed results on tricuspid
annulus plane systolic excursion and NT-proBNP level were
observed, because patients with an atrial septal defect had
a positive correlation and patients with a congenitally
corrected TGA had a signiﬁcant negative correlation. In
patients with Fontan circulation who had moderate to
severely impaired ventricular function, NT-proBNP values
were signiﬁcantly higher in patients with Fontan circulation
who had normal or only mildly impaired ventricular function
after adjustment for age and sex (p ¼ 0.023).
DIASTOLIC FUNCTION. The diastolic function parametersE/E0
ratio, E0, and A-wave showed a signiﬁcant correlation with
NT-proBNP values in patients with AoS, CoA, and ToF.
Such relationshipswere not observed in patientswith any of the
other diagnoses. No relationship between NT-proBNP level
and deceleration time or E/A ratio was observed.
Table 1 Baseline Characteristics
All Patients AoS CoA ASD ToF
TGA
ccTGA Fontan CirculationASO Mustard Procedure
General
n 475 88 59 48 168 27 50 11 24
Age (yrs) 34  12 34  12 32  13 43  5 35  13 22  2 35  5 42  15 28  9
Corrective surgery (%) 93 72 97 100 100 100 100 55 100
Age at corrective surgery (yrs) 7  10 23  12 7  11 7  3 5  7 0.4  2 1  2 26  14 4  3
Male (%) 57 63 56 35 59 48 68 64 54
Body mass index (kg/m2) 25  4 25  4 25  5 25  4 24  4 23  3 25  5 25  3 23  4
Systolic blood pressure (mm Hg) 125  16 124  15 129  17 130  19 125  16 122  12 124  15 126  15 122  16
Diastolic blood pressure (mm Hg) 79  11 78  10 80  11 80  12 78  12 76  9 80  12 82  10 76  12
Heart rate (beats/min) 73  14 75  13 70  14 71  12 76  13 65  13 72  14 75  9 74  13
Oxygen saturation 99 (76–100) 99 (95–100) 99 (95–100) 98 (94–100) 98 (76–100) 100 (97–100) 97 (88–100) 100 (95–100) 95 (80–100)
NYHA functional class
I 426 (90) 83 (94) 59 (100) 46 (96) 149 (89) 27 (100) 37 (74) 10 (91) 15 (63)
II 45 (9) 4 (5) 0 2(4) 18 (10) 0 12 (24) 1 (9) 8 (33)
III 4 (1) 1 (1) 0 0 1 (1) 0 1 (2) 0 1 (4)
Electrocardiogram
Rhythm
Sinus rhythm 412 (87) 81 (92) 57 (96) 46 (96) 140 (84) 26 (96) 39 (78) 4 (36) 19 (80)
Atrial ﬁbrillation/ﬂutter 13 (3) 2 (2) 1 (2) 0 4 (2) 0 1( (2) 2 (18) 1 (4)
Paced rhythm 34 (7) 5 (6) 0 0 17 (10) 0 6 (12) 4 (36) 2 (8)
Atrial/nodal rhythm 16 (3) 0 1 (2) 2(4) 7 (4) 1 (4) 4 (8) 1 (10) 2 (8)
QRS duration (ms) 122  30 106  21 111  18 101  12 144  32 110  21 122  25 111  14 116  19
If QRS >120 ms: RBBB/LBBB/unspeciﬁed 167/16/41 9/3/9 11/6/12 1/0/2 110/2/10 6/0/4 26/1/1 0/1/0
Values are n, mean  SD, or n (%).
AoS ¼ aortic stenosis; ASD¼ atrial septal defect; ASO ¼ arterial switch operation; ccTGA ¼ congenitally corrected transposition of the great arteries; CoA ¼ aortic coarctation; LBBB ¼ left bundle branch block; NYHA ¼ New York Heart Association; RBBB ¼ right bundle branch
block; TGA ¼ transposition of the great arteries; ToF ¼ tetralogy of Fallot.
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Figure 1 NT-proBNP Levels by Type of Congenital Heart Disease
An overview of the median (range) of NT-proBNP levels for all included cardiac diagnoses. For each diagnosis, the percentage of patients with NT-proBNP levels above the
reference value of 14 pmol/l is presented. Furthermore, the percentage of patients with levels of NT-proBNP 3 times the reference value or higher is shown. AoS ¼ aortic
stenosis; ASD ¼ atrial septal defect; ASO ¼ arterial switch operation; ccTGA ¼ congenitally corrected transposition of the great arteries; CoA ¼ aortic coarctation;
Fontan ¼ Fontan circulation; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; TGA ¼ transposition of the great arteries; ToF ¼ tetralogy of Fallot.
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1207Exercise test and NT-proBNP levels. Bicycle ergometry
was performed in 198 patients (42%). Additionally, oxygen
uptake was measured in 103 patients (22%) during the test.
In 48% of the patients, a workloadmax of 85% of predicted
was not reached. VO2max was decreased in 61% of the
patients (Table 4). A higher logNT-proBNP level was
associated with lower workloadmax (b ¼ 0.08, p ¼ 0.021)
and lower VO2max (b ¼ 0.012, p ¼ 0.011) in a multivari-
able regression model adjusted for age and sex.
Discussion
This cross-sectional study focused on NT-proBNP
outcomes in adults with CHD. Clear differences in NT-
proBNP levels among patients with various congenital
heart defects were shown. NT-proBNP levels ranged from
mostly normal levels in patients with CoA to highly elevated
levels in the majority of patients with complex CHD,
including patients with a systemic RV or Fontan circulation.
Because this cross-sectional study shows results comparable
to ﬁndings by Popelova et al. (7), the presented values can
possibly be used as reference values of NT-proBNP per
cardiac diagnosis. As more patients with CHD reach
adulthood, many will encounter late complications. To
determine the additional prognostic value of NT-proBNP,
further ﬁne-tuning and follow-up data are clearly needed.
Despite remarkable differences in NT-proBNP levels, the
majority of patients were asymptomatic and in NYHAfunctional class I. Although NT-proBNP levels in asymp-
tomatic patients were already raised and none of our patients
were in NYHA class IV, our results suggest a positive
correlation between NT-proBNP level and NYHA classi-
ﬁcation, similar to the well-known correlation in patients
with congestive heart failure. NT-proBNP levels were
higher in women than in men, which extends previous
knowledge in acquired heart failure, and these higher levels
remain present over time (11). Consequently, sex-speciﬁc
reference values are mandatory, but a larger multicenter
study is needed.
We observed a clear relationship between NT-proBNP
level and atrial arrhythmias. This has previously been
found in patients with nonvalvular atrial ﬁbrillation, in
which higher NT-proBNP values were associated with an
increased risk of stroke and mortality (12). In patients with
CHD, atrial arrhythmias are an important source of mor-
bidity as well (13). Furthermore, a relationship between NT-
proBNP level and QRS duration was observed in patients
with a systemic RV and patients with ToF. A prolonged
QRS duration is associated with an increased mortality rate
in patients with ToF (14). Hence, NT-proBNP may have
a prognostic value.
In addition, the relationship between NT-proBNP level
and exercise capacity strengthens the possible use of NT-
proBNP as a prognostic marker, because exercise stress
testing provides strong prognostic information in adults with
CHD (15). Our observed distribution of NT-proBNP
Figure 2 Relationship Between NT-proBNP Levels and Baseline Characteristics
(A)Mean logNT-proBNP level by NYHA class. (B) Mean logNT-proBNP level by ECG rhythm. (C) Correlation between logNT-proBNP level and age. The dashed lines show the 95%
conﬁdence interval for the mean. (D) Correlation between logNT-proBNP level and QRS duration. The dashed lines show the 95% conﬁdence interval for the mean. ECG ¼
electrocardiographic; NYHA ¼ New York Heart Association; other abbreviations as in Figure 1.
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1208levels, with higher levels in those with more complex CHD,
is in line with ﬁndings of average exercise capacity as recently
reported by Kempny et al. (16). When compared with
healthy controls, both an increase in NT-proBNP level and
reduced peak VO2 were most pronounced in patients with
complex CHD.
Most importantly, signiﬁcant correlations between echo-
cardiographic parameters and NT-proBNP levels were
observed, with notable differences between the various types
of CHD.
Left-sided heart lesions. The strongest relationship
between left atrial size and NT-proBNP levels was observed
in patients with AoS. NT-proBNP may contribute to
detection of left atrial remodeling, which is directly associ-
ated with an increased mortality rate in asymptomatic
patients with a severe acquired aortic stenosis (17), and
similar results were found in patients with heart failure with
preserved ejection fraction (18). In line with the fact that
atrial size can indicate the presence of diastolic dysfunction
(19), several measures of diastolic function were related toNT-proBNP as well. These signiﬁcant relationships were
primarily seen in patients with left-sided cardiac pathology,
such as AoS and CoA. The pressure overload caused by the
aortic stenosis or previous hypertension in patients with
CoA could be the origin of impaired cardiac relaxation. A
recent observation suggests that after successful repair of
CoA, pediatric patients more often have diastolic dysfunc-
tion than healthy subjects (20). In patients with calciﬁed
aortic stenosis, NT-proBNP level was related to diastolic
function parameters (21). NT-proBNP could possibly be
a useful supplementary tool to identify diastolic functional
impairment in patients with left-sided lesions. Diastolic
dysfunction may be the most important clinical problem in
these patients.
Tetralogy of Fallot. In adults with corrected ToF, right
ventricular dysfunction and right ventricular annulus dilation
secondary to pulmonary regurgitation are major concerns
and have both been linked to release of NT-proBNP (22).
Nonetheless, we observed stronger relationships between
NT-proBNP and left heart side measures such as left
Table 2 Echocardiographic Findings
AoS CoA ASD ToF
TGA
ccTGA Fontan CirculationASO Mustard Procedure
LVEDD (mm/mm/m2) 50  6/26  4* 50  5/27  3* 48  6/25  3* 48  6/26  3* 51  6/28  3* NM NM 53  12/30  8*
LVESD (mm/mm/m2) 33  5/17  3* 31  6/16  3* 30  5/16  3* 32  6/18  4* 33  5/18  3* NM NM 36  13/21  8*
LA PLAX (mm) 36  7 35  7 38  7 38  7 34  8 NM NM 54  19
LA 4 CH L (mm) 56  8 53  8 56  7 56  9 56  7 NM 66  11 73  2
LA 4 CH T (mm) 42  7 38  5 42  5 40  6 37  5 NM 49  13 NM
RVD annulus (mm/mm/m2) 38  6/20  3* 39  6/21  3* 41  7/21  3* 46  8/24  4* 20  4* 51  6/27  3* 55  9/30  4* NM
RVD apex-base (mm/mm/m2) 83  7/44  5* 85  8/45  4* 65  7/34  5* 87  8/46  5* 45  5* 87  9/46  5* 80  6/42  5* NM
RA no/mild/severe dilation 18/9/5 42/8/3 21/16/1 44/59/48 20/4/1 1/13/32 3/7/0 NM
Systolic function
LVEF (%) 57  9 59  8 54  8 51  8 57  8 NM NM 51  5
Good/mild vs.
moderate/severe impaired
84/4 59/0 48/0 153/15 22/0 47/2 11/0 18/2
RV fractional area change (%) 45  8 45  8 43  9 41  10 43  7 25  8 25  8 NM
RV TAPSE (mm) 20  2 25  6 19  4 17  5 18  4 12  3 14  3 NM
Diastolic function (mitral inﬂow)
E/A ratio 1.62  0.67 1.69  0.5 1.33  0.4 1.69  0.7 2.39  0.9 1.75  0.9y 1.27  0.6y 1.46  0.5
E (m/s) 0.85  0.2 1.01  0.3 0.70  0.2 0.81  0.2 0.98  0.3 0.73  0.2y 0.98  0.3y 0.53  0.2
A (m/s) 0.58  0.2 0.63  0.21 0.55  0.2 0.52  0.2 0.42  0.1 0.51  0.3y 0.85  0.6y 0.41  0.5
Deceleration time (ms) 196  54 217  56 220  41 197  54 190  50 206  50y 219  109y 177  65
E/e0 ratio 10.9  4.0 12.3  5.3 8.4  5.0 11.0  4.3 9.6  3.8 NM NM NM
Values are mean  SD or n. *Indexed for body surface area. yTricuspid inﬂow.
LA 4CH L ¼ left atrial 4-chamber longitudinal dimension; LA 4CH T ¼ left atrium 4-chamber transversal dimension; LA PLAX ¼ left atrial dimension parasternal long axis; LVEDD ¼ left ventricular end-diastolic dimension; LVEF ¼ left ventricular ejection fraction; LVESD ¼ left
ventricular end-systolic dimension; NM ¼ not measured; RA ¼ right atrium; RV ¼ right ventricle; RVD ¼ right ventricular dimension; TAPSE ¼ tricuspid annulus plane systolic excursion; other abbreviations as in Table 1.
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Table 4 Exercise Test (n ¼ 198)
Workload, maximum (%) 85  20
<85% of predicted workload (%) 45
VO2max (%) 82  22
<85% of predicted VO2max (%) 61
RQ at peak exercise 1.3  0.2
RQ <1 (%) 1
Values are mean  SD or n.
RQ ¼ respiratory quotient; VO2max ¼ maximal oxygen uptake.
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1210ventricular ejection fraction and dimensions that strengthen
the hypothesis that these left heart problems are of main
concern in patients with repaired ToF. In contrast to 3 other
(smaller) studies that reported no relationship between
NT-proBNP level and left ventricular ejection fraction in
patients with ToF (23–25), our study did show a signiﬁcant
correlation. Furthermore, the relationship between NT-
proBNP levels and diastolic function conﬁrms the recent
ﬁndings of Friedberg et al. that diastolic dysfunction is an
important component in adults with ToF that occurs early in
the clinical course when patients are still asymptomatic (26).
A recent study reported an incidence of left ventricular
dysfunction of 21% in adults with corrected ToF, possibly
the result of prior long-standing cyanosis at young age before
repair, volume overload due to aortic regurgitation, or ad-
verse ventricular-ventricular interaction (27). An increasing
body of evidence suggests that left ventricular dysfunction is
encountered with increasing age in patients with corrected
ToF (27–29). NT-proBNP may contribute substantially to
diagnosis and follow-up of left ventricular systolic and dia-
stolic dysfunction.
Systemic RV. The highest NT-proBNP levels were found
in patients with a systemic RV and were mainly related to
right ventricular annulus dilation and decreased systemic
right ventricular function. In these patients, the enlarged RV
is primarily the result of right ventricular failure and may also
lead to functional tricuspid regurgitation. The RV is less well
suited to cope with high systemic pressure, possibly due to
its triangular geometry and distinct myocardial ﬁber orien-
tation. In our study, there were relationships between
neurohormonal activation and right ventricular function and
dimensions that are in line with previous studies, supporting
the possible use of this marker as a supplementary test to
monitor right ventricular function. Additionally, NT-
proBNP may contribute to the timing of an intervention
for tricuspid regurgitation (30). Early detection of decline in
right ventricular function is crucial because right ventricular
failure might result in death or serious morbidity requiring
cardiac transplantation (31). Diastolic function parameters
in patients with TGA after the Mustard procedure did not
correlate with NT-proBNP levels. However, measurement
of diastolic function using tricuspid valve inﬂow is disputable
in patients who have undergone the Mustard procedure
because of their stiff atria as a result of the intra-atrial bafﬂes
and extensive scar tissue.
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1211Arterial switch operation. In contrast to patients with
Mustard correction, patients with TGA corrected with ASO
had notably low NT-proBNP values, mirroring their good
clinical condition and good left ventricular and right
ventricular function. As the ASO procedure, ﬁrst described
in 1976 by Jatene et al. (32), has succeeded the Mustard
procedure, patients who undergo ASO are typically younger
than patients who undergo the Mustard procedure. Mid-
term follow-up shows that patients who undergo ASO do
well in early adulthood (33), although problems of the right
ventricular outﬂow tract and aortic regurgitation may arise.
This is the ﬁrst study to report data on NT-proBNP after
ASO and all patients were asymptomatic, so the use of
natriuretic peptides in these patients has to be determined in
a larger cohort and with longer duration of follow-up before
ﬁrm conclusions can be drawn. Nevertheless, the low NT-
proBNP levels in combination with the absence of symp-
toms are certainly promising for the long-term outcome of
these patients.
Fontan circulation. In patients with Fontan circulation,
elevated NT-proBNP levels were clearly related to decreased
systolic ventricular function. Diastolic function parameters
did not correlate with NT-proBNP levels. However, dia-
stolic function is difﬁcult to assess in patients with Fontan
circulation. Individual anatomic differences due to various
surgeries inﬂuenced the observed NT-proBNP values and
the number of patients with Fontan circulation in our study
was limited, so our results can probably not be extrapolated
to all patients with a functional univentricular heart and
should be interpreted with caution.
Study limitations. Although we attempted to create
homogeneous patient groups by dividing the patients into
well-deﬁned anatomy-based groups, individual differences
caused by surgical history and disease severity withhold us
from making ﬁrm conclusions.
Future perspectives. NT-proBNP levels can only be partly
explained by echocardiographic parameters because the
observed relationships were signiﬁcant but not strong.
Nonetheless, the relationship between NT-proBNP levels
and echocardiographic function parameters in patients with
congestive heart failure was similar (34). To evaluate the
exact impact of ventricular function on NT-proBNP levels,
extensive investigation for each cardiac diagnosis is needed,
including other possible inﬂuences such as arrhythmias,
valvular disease, and surgical history. This study is a ﬁrst
attempt to create disease-speciﬁc NT-proBNP reference
values for each congenital cardiac diagnosis. Finally, because
this is a cross-sectional study, only correlations can be given.
Longitudinal data will provide additional prognostic impli-
cations of these ﬁndings.
Conclusions
Levels of NT-proBNP clearly differ among various
congenital heart lesions. Remarkable disease-speciﬁc corre-
lations between NT-proBNP levels and echocardiographicparameters have been found. In patients with left-sided
pathology, a higher level of NT-proBNP correlates with
diastolic dysfunction parameters. In patients with a systemic
RV, NT-proBNP levels are inﬂuenced by right ventricular
dimension and right ventricular systolic function. In patients
with ToF, elevated NT-proBNP levels are typically associ-
ated with deterioration in left ventricular function as well as
left ventricular and left atrial dilation. Furthermore, NT-
proBNP levels are related to exercise capacity. Hence,
natriuretic peptides hold promise as a marker of cardiac
dysfunction in adults with CHD, but follow-up data are
needed to determine the prognostic value.
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